Describing An Investigational Drug On Your Website? Don’t Be Definitive About The Data, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues untitled letter to CBA Research Inc. for touting the safety and efficacy of CBT-1 as a cancer therapy on the company website although the agency has yet to complete review of an NDA for the drug.